IP Library › Granted Patent US 7,306,927
Granted Patent B2
US 7,306,927 · App. 09/905,083 · Granted Dec 11, 2007

Method of inducing immunity against stratum corneum chymotrytic enzyme

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,306,927
App. No.
09/905,083
Granted
Dec 11, 2007
Kind
B2
Abstract

The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and their presence may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.

Claims (3)

1. A method of producing activated T cells directed toward stratum corneum chymotrytic enzyme (SCCE) comprising the steps of:

exposing dendritic cells to a humam SCCE peptide selected from the group consisting of SEQ ID Nos. 32, 33, 35, 36, 86 or the human SCCE protein encoded by the DNA of SEQ ID NO: 30, thereby producing activated dendritic cells; and

exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said SCCE peptide to said T cells, thereby producing activated T cells directed toward said SCCE.